NASDAQ:BCRX - BioCryst Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$8.19 -0.07 (-0.85 %)
(As of 12/17/2018 02:06 PM ET)
Previous Close$8.26
Today's Range$8.13 - $8.51
52-Week Range$4.25 - $9.70
Volume20,668 shs
Average Volume697,553 shs
Market Capitalization$905.64 million
P/E Ratio-10.51
Dividend YieldN/A
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan. It also develops BCX7353 and second generation kallikrein inhibitors, which are oral serine protease inhibitors targeting plasma kallikrein for hereditary angioedema; BCX9250 and BCX9499, which are activin receptor-like kinase-2 inhibitors for fibrodysplasia ossificans progressive; and Galidesivir, a RNA dependent-RNA polymerase inhibitor to treat RNA viruses. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Receive BCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Current SymbolNASDAQ:BCRX
Previous Symbol


Debt-to-Equity Ratio0.43
Current Ratio2.00
Quick Ratio1.98


Trailing P/E Ratio-10.51
Forward P/E Ratio-8.27
P/E GrowthN/A

Sales & Book Value

Annual Sales$25.19 million
Price / Sales35.65
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.85 per share
Price / Book9.64


EPS (Most Recent Fiscal Year)($0.78)
Net Income$-65,780,000.00
Net Margins-428.00%
Return on Equity-141.00%
Return on Assets-58.48%


Outstanding Shares109,640,000
Market Cap$905.64 million

BioCryst Pharmaceuticals (NASDAQ:BCRX) Frequently Asked Questions

What is BioCryst Pharmaceuticals' stock symbol?

BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."

How were BioCryst Pharmaceuticals' earnings last quarter?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) released its quarterly earnings data on Tuesday, November, 6th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.25) by $0.03. The biotechnology company earned $1.45 million during the quarter, compared to the consensus estimate of $2.53 million. BioCryst Pharmaceuticals had a negative net margin of 428.00% and a negative return on equity of 141.00%. View BioCryst Pharmaceuticals' Earnings History.

When is BioCryst Pharmaceuticals' next earnings date?

BioCryst Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for BioCryst Pharmaceuticals.

What price target have analysts set for BCRX?

9 equities research analysts have issued twelve-month target prices for BioCryst Pharmaceuticals' stock. Their forecasts range from $6.00 to $16.00. On average, they expect BioCryst Pharmaceuticals' stock price to reach $11.9286 in the next twelve months. This suggests a possible upside of 45.8% from the stock's current price. View Analyst Price Targets for BioCryst Pharmaceuticals.

What is the consensus analysts' recommendation for BioCryst Pharmaceuticals?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioCryst Pharmaceuticals.

What are Wall Street analysts saying about BioCryst Pharmaceuticals stock?

Here are some recent quotes from research analysts about BioCryst Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. " (11/7/2018)
  • 2. HC Wainwright analysts commented, "NewCo Combines HAE Commercial & Deal-Making Expertise With Core Competency in Structure-Based Drug Design Diversification and management expertise drive the deal. Biocryst today announced its intention to merge with the oligomer company Idera (IDRA; Buy Rated) to form a NewCo that will continue to develop treatments for both HAE as well as checkpoint-refractory myeloma." (1/23/2018)

Has BioCryst Pharmaceuticals been receiving favorable news coverage?

News headlines about BCRX stock have trended somewhat positive on Monday, InfoTrie reports. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BioCryst Pharmaceuticals earned a daily sentiment score of 1.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are some of BioCryst Pharmaceuticals' key competitors?

Who are BioCryst Pharmaceuticals' key executives?

BioCryst Pharmaceuticals' management team includes the folowing people:
  • Mr. Jon P. Stonehouse, CEO, Pres & Director (Age 57)
  • Mr. Thomas R. Staab II, CFO, Principal Accounting Officer, Sr. VP & Treasurer (Age 50)
  • Dr. William P. Sheridan, Chief Medical Officer & Sr. VP (Age 63)
  • Dr. Yarlagadda S. Babu, Sr. VP of Drug Discovery (Age 65)
  • Ms. Lynne M. Powell, Chief Commercial Officer & Sr. VP (Age 51)

Who are BioCryst Pharmaceuticals' major shareholders?

BioCryst Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Baker BROS. Advisors LP (13.78%), Janus Henderson Group PLC (11.18%), BlackRock Inc. (8.00%), Vanguard Group Inc. (5.29%), Vanguard Group Inc (5.29%) and Jennison Associates LLC (3.51%). Company insiders that own BioCryst Pharmaceuticals stock include Alane P Barnes, Fred E Cohen, Lynne Powell, Thomas R Staab II and William P Sheridan. View Institutional Ownership Trends for BioCryst Pharmaceuticals.

Which major investors are selling BioCryst Pharmaceuticals stock?

BCRX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Renaissance Technologies LLC, Virtus ETF Advisers LLC, Morgan Stanley, TIAA CREF Investment Management LLC, Credit Suisse AG and Citadel Advisors LLC. Company insiders that have sold BioCryst Pharmaceuticals company stock in the last year include Alane P Barnes, Lynne Powell, Thomas R Staab II and William P Sheridan. View Insider Buying and Selling for BioCryst Pharmaceuticals.

Which major investors are buying BioCryst Pharmaceuticals stock?

BCRX stock was acquired by a variety of institutional investors in the last quarter, including VHCP Management III LLC, Janus Henderson Group PLC, Baker BROS. Advisors LP, BlackRock Inc., VHCP Management II LLC, Vanguard Group Inc, Vanguard Group Inc. and Jennison Associates LLC. View Insider Buying and Selling for BioCryst Pharmaceuticals.

How do I buy shares of BioCryst Pharmaceuticals?

Shares of BCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioCryst Pharmaceuticals' stock price today?

One share of BCRX stock can currently be purchased for approximately $8.18.

How big of a company is BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals has a market capitalization of $905.64 million and generates $25.19 million in revenue each year. The biotechnology company earns $-65,780,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis. BioCryst Pharmaceuticals employs 85 workers across the globe.

What is BioCryst Pharmaceuticals' official website?

The official website for BioCryst Pharmaceuticals is

How can I contact BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The biotechnology company can be reached via phone at 919-859-1302 or via email at [email protected]

MarketBeat Community Rating for BioCryst Pharmaceuticals (NASDAQ BCRX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  352 (Vote Outperform)
Underperform Votes:  326 (Vote Underperform)
Total Votes:  678
MarketBeat's community ratings are surveys of what our community members think about BioCryst Pharmaceuticals and other stocks. Vote "Outperform" if you believe BCRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/17/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel